ClinicalTrials.gg

Program

LY3938577

A development code.

In Eli Lilly's pipeline, insulin receptor agonist. Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Eli Lilly.

Furthest: phase 2, since Oct 9, 20253 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly31 open or runningphase 2since Oct 9, 2025Nov 10, 2023Nov 2026phase 2 · NCT07215312
  • Named in Eli Lilly’s own pipeline as GS Insulin Receptor Agonist, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 10, 2023First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT06132126 · 66 enrolled · United States
  2. Feb 20, 2024Phase 1 study in Diabetes Mellitus, Type 1NCT06280703 · 121 enrolled · Germany
  3. Oct 9, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT07215312 · 100 enrolled · United States, Argentina

Ahead

  1. Nov 2026Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07215312

TargetBeta

“insulin receptor agonist”the company's pipeline, read by Claude · source

Other programs on INSR

ProgramCompanyFurthest phaseStudies
Insulin GlargineruleSanofiphase 4190
Insulin AspartruleNovo Nordiskphase 4146
insulin degludecruleNovo Nordiskphase 4108
InsulinrulePfizerphase 450
insulin glulisineruleSanofiphase 443
insulin icodecruleNovo Nordiskphase 430
linsitinibruleAstellas Pharmaphase 313

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07215312Diabetes Mellitus, Type 2 · United States, Argentina2Active, not recruitingNov 2026100
NCT06280703Diabetes Mellitus, Type 1 · Germany1CompletedOct 3, 2026121
NCT06132126Diabetes Mellitus, Type 2 · United States1CompletedJun 28, 202466

How it is read

Names in the registry

  • “LY3938577”, 4 entries

Codes read as this program: LY3938577.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.